

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 22, 2003, 15:06:54 ; Search time 86 Seconds  
(without alignments)  
645.980 Million cell updates/sec

Title: US-09-745-506-37  
Perfect score: 350  
Sequence: 1 MDLKAISLNDFAISFAE.....LEKNITILSETRDPLQYV 350

Scoring table: OLIGO  
Gapop 60.0 , Gapext 60.0

Searched: 1107863 seqs, 158726573 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database :

A.Geneseq\_19Jun03:\*  
1: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1980.DAT:\*  
2: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1981.DAT:\*  
3: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1982.DAT:\*  
4: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1983.DAT:\*  
5: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1984.DAT:\*  
6: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1985.DAT:\*  
7: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1986.DAT:\*  
8: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1987.DAT:\*  
9: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1988.DAT:\*  
10: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1989.DAT:\*  
11: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1990.DAT:\*  
12: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1991.DAT:\*  
13: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1992.DAT:\*  
14: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1993.DAT:\*  
15: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1994.DAT:\*  
16: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1995.DAT:\*  
17: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1996.DAT:\*  
18: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1997.DAT:\*  
19: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1998.DAT:\*  
20: /SIDSI/gcgdata/geneseq/genesep-emb1/AA1999.DAT:\*  
21: /SIDSI/gcgdata/geneseq/genesep-emb1/AA2000.DAT:\*  
22: /SIDSI/gcgdata/geneseq/genesep-emb1/AA2001.DAT:\*  
23: /SIDSI/gcgdata/geneseq/genesep-emb1/AA2002.DAT:\*  
24: /SIDSI/gcgdata/geneseq/genesep-emb1/AA2003.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	350	100.0	350	22	AA81361 Human AFP protein
2	350	100.0	350	22	AB94573 Human protein sequ
3	350	100.0	350	22	AA88085 Human immune/haema
4	296	84.6	377	22	AA027744 Human full-length
5	268	76.6	351	22	AB60663 Human gene express
6	211	60.3	247	23	AB808182 Human protein kina
7	102	29.1	110	22	ABG20985 Novel human diagno
8	68	19.4	68	22	ABG52473 Human liver peptid
9	68	19.4	68	22	AB832385 Peptide #5036 enco

10	68	19.4	68	22	AB837667 Peptide #5173 enco
11	68	19.4	68	22	AA58295 Human brain expres
12	68	19.4	68	22	AA18660 Peptide #5043 enco
13	68	19.4	68	22	AA06178 Peptide #4060 enco
14	49	14.0	79	22	AA021467 Human novel foetal
15	43	12.3	146	22	AA027916 Human contig poly
16	38	10.9	70	22	ABG20982 Novel human diagno
17	25	7.1	74	22	ABG20984 Novel human diagno
18	10	2.9	360	22	AA88258 S. epidermidis ope
19	10	2.9	367	22	ABP38833 Staphylococcus epi
20	8	2.3	64	22	AA021906 Human cardiovascular
21	7	2.0	15	18	AA019390 Human calpastatin
22	7	2.0	39	22	ABG51377 Human liver peptid
23	7	2.0	39	22	AB831334 Peptide #3975 enco
24	7	2.0	39	22	AB836530 Peptide #4036 enco
25	7	2.0	39	22	AB821871 Protein #3870 enco
26	7	2.0	39	22	AA057293 Human bone marrow
27	7	2.0	39	22	AA069697 Human brain expres
28	7	2.0	39	22	AA017509 Peptide #3943 enco
29	7	2.0	39	22	AA030031 Peptide #4068 enco
30	7	2.0	39	22	AA005181 Peptide #3863 enco
31	7	2.0	39	23	ABG39312 Human peptid enco
32	7	2.0	52	21	AA056482 Arabidopsis thaila
33	7	2.0	52	21	AA058744 Arabidopsis thaila
34	7	2.0	56	23	ABP42537 Human ovarian anti
35	7	2.0	66	22	AA054473 Propionibacterium
36	7	2.0	68	15	AA046082 DEAD ATP helicase
37	7	2.0	80	22	AA096296 Human reproductive
38	7	2.0	93	22	AA078718 Human pterin-molyb
39	7	2.0	116	21	AA009953 Rice disease resis
40	7	2.0	119	22	AA011178 Mycobacterium aviu
41	7	2.0	141	22	AB011967 Drosophila melanog
42	7	2.0	157	21	AA017053 Arabidopsis thaila
43	7	2.0	164	22	AB070532 Drosophila melanog
44	7	2.0	166	23	ABP51404 Human MDPT SEQ ID
45	7	2.0	168	22	AA093880 Human protein sequ

#### ALIGNMENTS

RESULT 1	
AA81361	
ID	AA81361 standard; Protein; 350 AA.
XX	
AC	AA81361;
XX	
DT	10-SEP-2001 (first entry)
XX	
DE	Human AFP protein sequence SEQ ID NO:240.
XX	
KW	Human; secreted protein; secretion; bacterial cell; fungal cell;
KW	eukaryotic cell; fusion protein; maltose binding protein;
KW	immunoglobulin constant region; polyhistidine tag.
XX	
OS	Homo sapiens.
XX	
PN	W0200129221-A2.
XX	
PD	26-APR-2001.
XX	
PF	20-OCT-2000; 2000MO-US29052.
XX	
PR	20-OCT-1999; 99US-0160712.
XX	
PA	(ZYMO) ZYMOGENETICS INC.
XX	
PI	Conklin DC, Yee DP;
XX	
DR	WPI: 2001-300340/31.
DR	N-PSDB; AA052212.
XX	
PT	Isolated polypeptide for directing secretion of proteins of interest

from a host cell including, e.g. bacteria, includes contiguous amino acid residues of polypeptide with specified amino acids -

Claim 1; Page 424-425; 617pp; English.

AAH52093 to AAH52303 encode the human secreted proteins given in AAG81242 to AAG8153. The secreted proteins can be used for directing the secretion of proteins of interest from a host cell including bacteria, fungal cells, and cultured higher eukaryotic cells. The present invention also describes fusion proteins, where a secreted protein of the invention is operably linked via a peptide bond or peptide linker to a second protein selected from the group consisting of maltose binding protein, an immunoglobulin constant region, a polynitidine tag and a peptide given in AAG81453.

Sequence 350 AA;

Query Match 100.0%; Score 350; DB 22; Length 350;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 350; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MDKALLSLNDFASLSFAESMDNVGLVPESPPTVTLEFLTNDLFEVMEVYLQKKAD 60  
1 MDKALLSLNDFASLSFAESMDNVGLVPESPPTVTLEFLTNDLFEVMEVYLQKKAD 60  
61 LILSYHPPIFRPMKRITWNTWKEKRLVIRALENRGVTSPHTAYDAAPGVNNMLAKGIGA 120  
61 LILSYHPPIFRPMKRITWNTWKEKRLVIRALENRGVTSPHTAYDAAPGVNNMLAKGIGA 120  
121 CTSRPIHPSKAPNPTGSHNHRVEFNVTODLDKVMASVKIGDGVTSFSFARFGENEOT 180  
121 CTSRPIHPSKAPNPTGSHNHRVEFNVTODLDKVMASVKIGDGVTSFSFARFGENEOT 180  
121 CTSRPIHPSKAPNPTGSHNHRVEFNVTODLDKVMASVKIGDGVTSFSFARFGENEOT 180  
181 RINLNCOTKALMQVYDFLSRNKQLYOKTEILSLKPLLHTGMGRCLTLDSEVSILATMID 240  
181 RINLNCOTKALMQVYDFLSRNKQLYOKTEILSLKPLLHTGMGRCLTLDSEVSILATMID 240  
181 RINLNCOTKALMQVYDFLSRNKQLYOKTEILSLKPLLHTGMGRCLTLDSEVSILATMID 240  
241 RIKRHLKLSHRLALGVGRITLESQVYVALCAGSSSVLQGVADLYLTGEMSHHDTIDA 300  
241 RIKRHLKLSHRLALGVGRITLESQVYVALCAGSSSVLQGVADLYLTGEMSHHDTIDA 300  
241 RIKRHLKLSHRLALGVGRITLESQVYVALCAGSSSVLQGVADLYLTGEMSHHDTIDA 300  
301 ASQGINVILCEHSNTERGFLSDLRMDLSHLENKINIILSETDRDPLQVY 350  
301 ASQGINVILCEHSNTERGFLSDLRMDLSHLENKINIILSETDRDPLQVY 350  
301 ASQGINVILCEHSNTERGFLSDLRMDLSHLENKINIILSETDRDPLQVY 350

RESULT 2  
AAB94573  
ID AAB94573 standard; Protein; 350 AA.

26-JUN-2001 (first entry)

Human protein sequence SEQ ID NO:15360.

Human; primer: detection; diagnosis; antisense therapy; gene therapy.

Homo sapiens.

EP1074617-A2.

07-FEB-2001.

28-JUL-2000; 2000EP-0116126.

29-JUL-1999; 99JP-0248036.  
27-AUG-1999; 99JP-0300253.  
11-JAN-2000; 2000JP-0118776.  
02-MAY-2000; 2000JP-0183767.  
09-JUN-2000; 2000JP-0241899.

(HELI-) HELIX RES INST.

Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;  
Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;  
WPI; 2001-318749/34.

Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs -

Claim 8; SEQ ID 15360; 2537pp + CD ROM; English.

The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesizing polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95883 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention.

Sequence 350 AA;

Query Match 100.0%; Score 350; DB 22; Length 350;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 350; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MDKALLSLNDFASLSFAESMDNVGLVPESPPTVTLEFLTNDLFEVMEVYLQKKAD 60  
1 MDKALLSLNDFASLSFAESMDNVGLVPESPPTVTLEFLTNDLFEVMEVYLQKKAD 60  
61 LILSYHPPIFRPMKRITWNTWKEKRLVIRALENRGVTSPHTAYDAAPGVNNMLAKGIGA 120  
61 LILSYHPPIFRPMKRITWNTWKEKRLVIRALENRGVTSPHTAYDAAPGVNNMLAKGIGA 120  
121 CTSRPIHPSKAPNPTGSHNHRVEFNVTODLDKVMASVKIGDGVTSFSFARFGENEOT 180  
121 CTSRPIHPSKAPNPTGSHNHRVEFNVTODLDKVMASVKIGDGVTSFSFARFGENEOT 180  
121 CTSRPIHPSKAPNPTGSHNHRVEFNVTODLDKVMASVKIGDGVTSFSFARFGENEOT 180  
181 RINLNCOTKALMQVYDFLSRNKQLYOKTEILSLKPLLHTGMGRCLTLDSEVSILATMID 240  
181 RINLNCOTKALMQVYDFLSRNKQLYOKTEILSLKPLLHTGMGRCLTLDSEVSILATMID 240  
181 RINLNCOTKALMQVYDFLSRNKQLYOKTEILSLKPLLHTGMGRCLTLDSEVSILATMID 240  
241 RIKRHLKLSHRLALGVGRITLESQVYVALCAGSSSVLQGVADLYLTGEMSHHDTIDA 300  
241 RIKRHLKLSHRLALGVGRITLESQVYVALCAGSSSVLQGVADLYLTGEMSHHDTIDA 300  
241 RIKRHLKLSHRLALGVGRITLESQVYVALCAGSSSVLQGVADLYLTGEMSHHDTIDA 300  
301 ASQGINVILCEHSNTERGFLSDLRMDLSHLENKINIILSETDRDPLQVY 350  
301 ASQGINVILCEHSNTERGFLSDLRMDLSHLENKINIILSETDRDPLQVY 350  
301 ASQGINVILCEHSNTERGFLSDLRMDLSHLENKINIILSETDRDPLQVY 350

RESULT 3  
AAM88085  
ID AAM88085 standard; Protein; 363 AA.

AAM88085;

DT	07-NOV-2001 (first entry)	PR	14-SEP-2000; 2000US-0233064.
XX		PR	14-SEP-2000; 2000US-0233065.
DE	Human immune/haematopoietic antigen SEQ ID NO:15678.	PR	21-SEP-2000; 2000US-0234223.
XX		PR	21-SEP-2000; 2000US-0234274.
KW	Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;	PR	25-SEP-2000; 2000US-0234597.
KW	cytostatic; gene therapy; vaccine; metastasis.	PR	25-SEP-2000; 2000US-0234598.
XX		PR	26-SEP-2000; 2000US-0235484.
OS	Homo sapiens.	PR	27-SEP-2000; 2000US-0235834.
XX		PR	27-SEP-2000; 2000US-0235836.
PN	WO200157182-A2.	PR	29-SEP-2000; 2000US-0236327.
XX		PR	29-SEP-2000; 2000US-0236367.
PD	09-AUG-2001.	PR	29-SEP-2000; 2000US-0236368.
XX		PR	29-SEP-2000; 2000US-0236369.
PF	17-JAN-2001; 2001WO-US01354.	PR	29-SEP-2000; 2000US-0236370.
XX		PR	02-OCT-2000; 2000US-0236802.
PR	31-JAN-2000; 2000US-0179065.	PR	02-OCT-2000; 2000US-0237037.
PR	04-FEB-2000; 2000US-0180628.	PR	02-OCT-2000; 2000US-0237038.
PR	24-FEB-2000; 2000US-0184664.	PR	02-OCT-2000; 2000US-0237039.
PR	02-MAR-2000; 2000US-0186350.	PR	02-OCT-2000; 2000US-0237040.
PR	16-MAR-2000; 2000US-0189874.	PR	13-OCT-2000; 2000US-0239935.
PR	17-MAR-2000; 2000US-0190076.	PR	13-OCT-2000; 2000US-0239937.
PR	18-APR-2000; 2000US-0198123.	PR	20-OCT-2000; 2000US-0240360.
PR	19-MAY-2000; 2000US-0203515.	PR	20-OCT-2000; 2000US-0240360.
PR	07-JUN-2000; 2000US-0209467.	PR	20-OCT-2000; 2000US-0241221.
PR	30-JUN-2000; 2000US-0214886.	PR	20-OCT-2000; 2000US-0241785.
PR	07-JUL-2000; 2000US-0215135.	PR	20-OCT-2000; 2000US-0241786.
PR	07-JUL-2000; 2000US-0216647.	PR	20-OCT-2000; 2000US-0241787.
PR	11-JUL-2000; 2000US-0216880.	PR	20-OCT-2000; 2000US-0241808.
PR	11-JUL-2000; 2000US-0217487.	PR	20-OCT-2000; 2000US-0241809.
PR	11-JUL-2000; 2000US-0217496.	PR	20-OCT-2000; 2000US-0241826.
PR	14-JUL-2000; 2000US-0218290.	PR	01-NOV-2000; 2000US-0244617.
PR	26-JUL-2000; 2000US-0220963.	PR	08-NOV-2000; 2000US-0246474.
PR	26-JUL-2000; 2000US-0220964.	PR	08-NOV-2000; 2000US-0246475.
PR	14-AUG-2000; 2000US-0224518.	PR	08-NOV-2000; 2000US-0246476.
PR	14-AUG-2000; 2000US-0224519.	PR	08-NOV-2000; 2000US-0246477.
PR	14-AUG-2000; 2000US-0225213.	PR	08-NOV-2000; 2000US-0246478.
PR	14-AUG-2000; 2000US-0225214.	PR	08-NOV-2000; 2000US-0246523.
PR	14-AUG-2000; 2000US-0225266.	PR	08-NOV-2000; 2000US-0246524.
PR	14-AUG-2000; 2000US-0225267.	PR	08-NOV-2000; 2000US-0246525.
PR	14-AUG-2000; 2000US-0225268.	PR	08-NOV-2000; 2000US-0246526.
PR	14-AUG-2000; 2000US-0225270.	PR	08-NOV-2000; 2000US-0246527.
PR	14-AUG-2000; 2000US-0225447.	PR	08-NOV-2000; 2000US-0246528.
PR	14-AUG-2000; 2000US-0225757.	PR	08-NOV-2000; 2000US-0246532.
PR	14-AUG-2000; 2000US-0225758.	PR	08-NOV-2000; 2000US-0246609.
PR	14-AUG-2000; 2000US-0225759.	PR	08-NOV-2000; 2000US-0246610.
PR	18-AUG-2000; 2000US-0226279.	PR	08-NOV-2000; 2000US-0246611.
PR	22-AUG-2000; 2000US-0226681.	PR	08-NOV-2000; 2000US-0246613.
PR	22-AUG-2000; 2000US-0226688.	PR	17-NOV-2000; 2000US-0249207.
PR	22-AUG-2000; 2000US-0227182.	PR	17-NOV-2000; 2000US-0249208.
PR	23-AUG-2000; 2000US-0227009.	PR	17-NOV-2000; 2000US-0249209.
PR	30-AUG-2000; 2000US-0228924.	PR	17-NOV-2000; 2000US-0249210.
PR	01-SEP-2000; 2000US-0229287.	PR	17-NOV-2000; 2000US-0249211.
PR	01-SEP-2000; 2000US-0229343.	PR	17-NOV-2000; 2000US-0249212.
PR	01-SEP-2000; 2000US-0229344.	PR	17-NOV-2000; 2000US-0249213.
PR	01-SEP-2000; 2000US-0229345.	PR	17-NOV-2000; 2000US-0249214.
PR	05-SEP-2000; 2000US-0229509.	PR	17-NOV-2000; 2000US-0249215.
PR	05-SEP-2000; 2000US-0229513.	PR	17-NOV-2000; 2000US-0249216.
PR	06-SEP-2000; 2000US-0230437.	PR	17-NOV-2000; 2000US-0249217.
PR	06-SEP-2000; 2000US-0230438.	PR	17-NOV-2000; 2000US-0249218.
PR	08-SEP-2000; 2000US-0231242.	PR	17-NOV-2000; 2000US-0249244.
PR	08-SEP-2000; 2000US-0231243.	PR	17-NOV-2000; 2000US-0249245.
PR	08-SEP-2000; 2000US-0231244.	PR	17-NOV-2000; 2000US-0249264.
PR	08-SEP-2000; 2000US-0231413.	PR	17-NOV-2000; 2000US-0249265.
PR	08-SEP-2000; 2000US-0231414.	PR	17-NOV-2000; 2000US-0249287.
PR	08-SEP-2000; 2000US-0232080.	PR	17-NOV-2000; 2000US-0249289.
PR	08-SEP-2000; 2000US-0232081.	PR	17-NOV-2000; 2000US-0249300.
PR	12-SEP-2000; 2000US-0231968.	PR	01-DEC-2000; 2000US-0250160.
PR	14-SEP-2000; 2000US-0232397.	PR	01-DEC-2000; 2000US-0250391.
PR	14-SEP-2000; 2000US-0232398.	PR	05-DEC-2000; 2000US-0251030.
PR	14-SEP-2000; 2000US-0232399.	PR	05-DEC-2000; 2000US-0251988.
PR	14-SEP-2000; 2000US-0232400.	PR	06-DEC-2000; 2000US-0256719.
PR	14-SEP-2000; 2000US-0232401.	PR	08-DEC-2000; 2000US-0251856.
PR	14-SEP-2000; 2000US-0233063.	PR	08-DEC-2000; 2000US-0251868.

PR 08-DEC-2000; 2000US-0251869.  
PR 08-DEC-2000; 2000US-0251989.  
PR 08-DEC-2000; 2000US-0251990.  
PR 11-DEC-2000; 2000US-0254097.  
PR 05-JAN-2001; 2001US-0259678.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Rosen CA, Barash SC, Ruben SM;  
XX  
XX WPI: 2001-483426/52.  
XX  
XX N-PSDB; AAK60866.  
XX  
XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
XX useful for preventing, diagnosing and/or treating cancers and  
XX metastasis -  
XX  
XX Claim 11; SEQ ID NO 15678; 3071pp + Sequence Listing; English.  
XX  
XX AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)  
XX amino acid sequences given in AAM82170 to AAM91921. (I) have cytosolic  
XX activity, and can be used in gene therapy and vaccine production. (I)  
XX proteins and polynucleotides may be used in the prevention, diagnosis and  
XX treatment of diseases associated with inappropriate (I) expression. For  
XX example, they may be used to treat disorders associated with decreased  
XX expression by rectifying mutations or deletions in a patient's genome  
XX that affect the activity of (I) by expressing inactive proteins or to  
XX supplement the patient's own production of (I). Additionally, (I)  
XX polynucleotides may be used to produce the secreted (I), by inserting  
XX the nucleic acids into a host cell and culturing the cell to express the  
XX protein. (I) proteins and polynucleotides may be used to prevent,  
XX diagnose and treat immune/hematopoietic-related diseases, especially  
XX cancers and cancer metastases of hematopoietic-derived cells. AAK64703  
XX to AAK67694 represent human immune/hematopoietic antigen genomic  
XX sequences from the present invention. AAK54942 to AAK54950 and AAM82169  
XX represent sequences used in the exemplification of the present invention.  
XX  
XX Sequence 383 AA:  
XX  
XX Query Match 100.0%; Score 350; DB 22; Length 383;  
XX Best Local Similarity 100.0%; Pred. No. 0;  
XX Matches 350; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX 1 MDLRAALLSLNDFASLSFAESMDNGLVBPSPHTVTMLFTNLTDEWMEVLOKRD 60  
XX |  
XX 34 MDLRAALLSLNDFASLSFAESMDNGLVBPSPHTVTMLFTNLTDEWMEVLOKRD 93  
XX |  
XX 61 LILSYHPIFRPMKRITWNWKERLVRALERNVGIYPHRYADAPOGVNMLAKGIGA 120  
XX |  
XX 94 LILSYHPIFRPMKRITWNWKERLVRALERNVGIYPHRYADAPOGVNMLAKGIGA 153  
XX |  
XX 121 CTSRPIHPSKAPNPTTEGNHRYEVNVTODLDKVMASVKGIDGVSVTSFSAKTGNEOT 180  
XX |  
XX 154 CTSRPIHPSKAPNPTTEGNHRYEVNVTODLDKVMASVKGIDGVSVTSFSAKTGNEOT 213  
XX |  
XX 181 RNLNCTOKALMOVYDFLSRNKOLQKTEILSLKPLLHNGMGSLCTIDESVSLATMID 240  
XX |  
XX 214 RNLNCTOKALMOVYDFLSRNKOLQKTEILSLKPLLHNGMGSLCTIDESVSLATMID 273  
XX |  
XX 241 RIKRRLKSHIRLALGVRTLESQYKVAALCAGSSSVYLOGEADLYLTGESHHDITDA 300  
XX |  
XX 274 RIKRRLKSHIRLALGVRTLESQYKVAALCAGSSSVYLOGEADLYLTGESHHDITDA 333  
XX |  
XX 301 ASOGINVLICHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVY 350  
XX |  
XX 334 ASOGINVLICHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVY 383  
XX |  
XX  
XX RESULT 4  
XX AAU27744  
XX ID AAU27744 standard; Protein; 377 AA.  
XX AC AAU27744;

XX  
XX 18-DEC-2001 (first entry)  
XX  
XX Human full-length polypeptide sequence #69.  
XX  
XX Mammal: human; rhesus monkey; baker's yeast; fission yeast; Norway rat;  
XX mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukemia;  
XX cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;  
XX nervous system disorder; inflammatory disorder; cell differentiation;  
XX angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;  
XX genetic disorder; bone regeneration; tendon; ligament; tissue repair;  
XX cytoskeletal; antirheumatic; antiarthritic; vulnery; antiinflammatory;  
XX antibacterial; immunosuppressive; vasotropic; antiparkinsonian;  
XX neuroprotective; osteopathic; antidiabetic; antisthmatic; antiallergic;  
XX immunostimulant; analgesic; gene therapy.  
XX  
XX Homo sapiens.  
XX  
XX WO200164834-A2.  
XX  
XX 07-SEP-2001.  
XX  
XX 26-FEB-2001; 2001WO-US04926.  
XX  
XX 28-FEB-2000; 2000US-0515126.  
XX 18-MAY-2000; 2000US-0577409.  
XX 17-JUN-2000; 2000US-0597707.  
XX 14-JUL-2000; 2000US-0616807.  
XX 19-SEP-2000; 2000US-0664641.  
XX  
XX (HSE-) HXSEQ INC.  
XX  
XX Tang YF, Liu C, Zhou P, Asundi V, Zhang J, Zhao QH, Ren F,  
XX Xue AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;  
XX Dmanac R;  
XX  
XX WPI: 2001-589862/66.  
XX N-PSDB; AAS44644.  
XX  
XX Novel polypeptides and nucleic acids obtained from cDNA libraries  
XX prepared from various human tissues, for diagnosis, treatment of  
XX cancer, neurological, inflammatory disorders and for use in arrays for  
XX detection -  
XX  
XX Claim 10; SEQ ID NO 241; 153pp; English.  
XX  
XX Sequences AAU27676-AAU28019 represent full-length polypeptides and  
XX contig polypeptides of the invention. The proteins and their associated  
XX DNA sequences are useful for the treatment, diagnosis and prevention of  
XX various types of disorder in a mammalian subject such as a human, dog,  
XX monkey, mouse, hamster or rat. The disorders include cancers such as  
XX leukemia, lymphoma and neuroblastoma, autoimmune disorders such as  
XX multiple sclerosis, connective tissue disease, rheumatoid arthritis,  
XX diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system  
XX disorders such as Parkinson's disease, Alzheimer's disease, Huntington's  
XX chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and  
XX Wernicke disease. Inflammatory disorders such as nephritis, Crohn's  
XX disease, ischemia-reperfusion injury, shock, sepsis and inflammatory  
XX bowel disease. The sequences exhibit actively relating to angiogenesis,  
XX cell proliferation, cell differentiation, stem cell growth factor,  
XX activin or inhibin. Therefore, they can be used to manipulate stem cells  
XX in culture to give rise to neuroepithelial cells that can be used to  
XX augment or replace cells damaged by illness, accidental damage or genetic  
XX disorders. The sequences may also be used for regeneration of bone,  
XX cartilage, tendons and ligaments and in tissue repair and burn healing.  
XX Note: Some sequences for this patent did not form part of the printed  
XX specification, but were obtained in electronic format directly from WIPO  
XX at ftp.wipo.int/pub/published\_pct\_sequences.  
XX  
XX Sequence 377 AA:  
XX  
XX Query Match 84.6%; Score 296; DB 22; Length 377;  
XX Best Local Similarity 100.0%; Pred. No. 8,4e-279;

Matches 296; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLKALLSLNDPASFASMDNVLVEPSPHTVNTLFLNDLTFEEVMEEVLDKKAD 60  
|||||  
Db 28 MDLKALLSLNDPASFASMDNVLVEPSPHTVNTLFLNDLTFEEVMEEVLDKKAD 87  
|||||  
QY 61 LILSYHPIIFRPMKRITMTWTKERLVRALENRVGIYSPHTAYDAAPQGVNMMIAKGLGA 120  
|||||  
Db 88 LILSYHPIIFRPMKRITMTWTKERLVRALENRVGIYSPHTAYDAAPQGVNMMIAKGLGA 147  
|||||  
QY 121 CTSRPHPSKAPRYPEEGHNRVEFNNTYODLDKMSAVKGDVSVTSFSAFTGNEOT 180  
|||||  
Db 148 CTSRPHPSKAPRYPEEGHNRVEFNNTYODLDKMSAVKGDVSVTSFSAFTGNEOT 207  
|||||  
QY 181 RINLNTCTOKALMOVDLFRNKOLYOKTEILSLERPLLHTGMRCTLDSEVSLATMTD 240  
|||||  
Db 208 RINLNTCTOKALMOVDLFRNKOLYOKTEILSLERPLLHTGMRCTLDSEVSLATMTD 267  
|||||  
QY 241 RIKRHLKLSHRLALGVGRTELSQVAVKAGSGSSVLDGVEADLYLTGEMSHHD 296  
|||||  
Db 268 RIKRHLKLSHRLALGVGRTELSQVAVKAGSGSSVLDGVEADLYLTGEMSHHD 323  
|||||

RESULT 5  
AAB60663  
ID AAB60663 standard; Protein; 351 AA.  
XX  
AC AAB60663;  
XX  
DT 04-MAY-2001 (first entry)  
XX  
DE Human gene expression regulatory factor-related protein hnrf3-s.  
XX  
KW Human gene expression regulatory factor-related protein; hnrf3-s;  
KW NG1-interacting factor; haemopoietic stem cell; preparation;  
KW detection.  
XX  
OS Homo sapiens.  
XX  
PN CN1272543-A.  
XX  
PD 08-NOV-2000.  
XX  
PF 11-APR-2000; 2000CN-0115369.  
XX  
PR 11-APR-2000; 2000CN-0115369.  
XX  
PA (NANF-) NANFANG RES CENT STATE HUMAN GENE GROUP.  
XX  
PI LI N', Xiao H, Liu F;  
XX  
DR WPI: 2001-183596/19.  
XX  
N-PSDB; AAF59945.  
XX  
PT Human gene expression regulatory factor related protein and its coded  
sequence -  
XX  
PS Claim 4; Page 19-20; 20pp; Chinese.  
XX  
CC The invention relates to a novel human gene expression regulatory  
CC factor-related protein, hnrf3-s (NG1-interacting factor, AAB60663),  
CC and cDNA encoding it (AAF59945). hnrf3-s is expressed in haemopoietic  
CC stem cells. The invention also relates to the preparation of hnrf3-s  
CC proteins and nucleic acids, and the detection of hnrf3-s proteins and  
CC nucleic acids in a sample. The present sequence represents hnrf3-s.  
XX  
SQ Sequence 351 AA:  
Query Match 76.6%; Score 268; DB 22; Length 351;  
Best Local Similarity 100.0%; Pred. No. 1.3e-251;  
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 83 ERLVIRALENRVGIYSPHTAYDAAPQGVNMMIAKGLGACTSRPIHPSKAPRYPEEGHNRV 142

Db 84 ERLVIRALENRVGIYSPHTAYDAAPQGVNMMIAKGLGACTSRPIHPSKAPRYPEEGHNRV 143  
|||||  
QY 143 ERFVNTYODLDKMSAVKGDVSVTSFSAFTGNEOTRINLNTCTOKALMOVDLFRNK 202  
|||||  
Db 144 ERFVNTYODLDKMSAVKGDVSVTSFSAFTGNEOTRINLNTCTOKALMOVDLFRNK 203  
|||||  
QY 203 QLYOKTEILSLERPLLHTGMRCTLDSEVSLATMTDRIKRLKLSHRLALGVGRTE 262  
|||||  
Db 204 QLYOKTEILSLERPLLHTGMRCTLDSEVSLATMTDRIKRLKLSHRLALGVGRTE 263  
|||||  
QY 263 SQKVVALCAGSGSSVLDGVEADLYLTGEMSHHDLDAAQGINVLICHSNTERGFLSD 322  
|||||  
Db 264 SQKVVALCAGSGSSVLDGVEADLYLTGEMSHHDLDAAQGINVLICHSNTERGFLSD 323  
|||||  
QY 323 LRDMDSHLENKINIIITSETDRPLOVY 350  
|||||  
Db 324 LRDMDSHLENKINIIITSETDRPLOVY 351  
|||||

RESULT 6  
ABB08182  
ID ABB08182 standard; Protein; 247 AA.  
XX  
AC ABB08182;  
XX  
DT 23-SEP-2002 (first entry)  
XX  
DE Human protein kinase C 27.17 polypeptide.  
XX  
KW Human; protein kinase C 27.17; protein metabolism; enzyme.  
XX  
OS Homo sapiens.  
XX  
PN CN1333355-A.  
XX  
PD 30-JAN-2002.  
XX  
PF 07-JUL-2000; 2000CN-0117049.  
XX  
PR 07-JUL-2000; 2000CN-0117049.  
XX  
PA (SHAN-) SHANGHAI BIODOOR GENE DEV CO LTD.  
XX  
PI Mao Y, Xie Y;  
XX  
DR WPI: 2002-305609/35.  
XX  
N-PSDB; ABL60919.  
XX  
PT Human protein kinase C 27.17 polypeptide and its encoding  
sequence -  
XX  
PS Claim 1; Page 26-27 (disclosure); 33pp; Chinese.  
XX  
CC The invention relates to a human protein kinase C 27.17 polypeptide and  
CC its encoding polynucleotide. The polypeptide can be expressed by standard  
CC DNA recombination. The polynucleotide, polypeptide and its antagonist are  
CC useful for treating e.g. protein metabolism disturbance. The present  
CC sequence represents the human protein kinase C 27.17 polypeptide.  
XX  
SQ Sequence 247 AA:  
Query Match 60.3%; Score 211; DB 23; Length 247;  
Best Local Similarity 100.0%; Pred. No. 2.2e-196;  
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 140 HRVEFVNTYODLDKMSAVKGDVSVTSFSAFTGNEOTRINLNTCTOKALMOVDLFRNK 199  
|||||  
Db 37 HRVEFVNTYODLDKMSAVKGDVSVTSFSAFTGNEOTRINLNTCTOKALMOVDLFRNK 96  
|||||  
QY 200 RNKOLYOKTEILSLERPLLHTGMRCTLDSEVSLATMTDRIKRLKLSHRLALGVGR 259  
|||||  
Db 97 RNKOLYOKTEILSLERPLLHTGMRCTLDSEVSLATMTDRIKRLKLSHRLALGVGR 156  
|||||



QY 51 MEEVLQKKADLLSYHPPIRPMKRITWNTWKERLVIRALENRVGISPTATDAAPGV 110  
DB 1 MEEVLQKKADLLSYHPPIRPMKRITWNTWKERLVIRALENRVGISPTATDAAPGV 60  
QY 111 NNMLAKGL 118  
DB 61 NNMLAKGL 68

## RESULT 9

ABB32385  
ID ABB32385 standard; Peptide; 68 AA.

AC ABB32385;

DT 01-FEB-2002 (first entry)

DE Peptide #5036 encoded by breast cell single exon nucleic acid probe.

KM Human; microarray; single exon probe; gene expression; breast;  
KM disease; cancer.

OS Homo sapiens.

PN W0200157271-A2.

PD 09-AUG-2001.

PF 30-JAN-2001; 2001MO-US00662.

PR 04-FEB-2000; 2000US-0180312.

PR 26-MAY-2000; 2000US-0207456.

PR 30-JUN-2000; 2000US-0608408.

PR 03-AUG-2000; 2000US-0632366.

PR 21-SEP-2000; 2000US-0234687.

PR 27-SEP-2000; 2000US-0236359.

PR 04-OCT-2000; 2000GB-0024263.

PA (MOLE-) MOLECULAR DYNAMICS INC.

PI Penn SG, Hanzel DK, Chen W, Rank DR;

DR WPI; 2001-496933/54.

XX New spatially-addressable set of single exon nucleic acid probes,  
PT useful for measuring gene expression in sample derived from human  
PT breast, comprises number of single exon nucleic acid probes -

PS Claim 27; SEQ ID NO 15353; 327pp + sequence listing; English.

XX The invention relates to a spatially-addressable set of single exon  
CC nucleic acid probes for measuring gene expression in a sample derived  
CC from human breast and BT 474 cells. The method involves contacting  
CC the probes with a collection of detectably labelled nucleic acids  
CC derived from mRNA of human breast, and then measuring the label  
CC bound to each probe of the microarray. The probes are useful for  
CC verifying the expression of regions of genomic DNA predicted to  
CC encode proteins. They are useful for gene discovery and for  
CC determining predisposition and/or prognosing breast disease. Gene  
CC expression analysis is useful for assessing the toxicity of chemical  
CC agents on cells. The microarray of this invention presents a far greater  
CC diversity of probes for measuring gene expression, with far less bias  
CC than expressed sequence tag microarrays. The method is suitable for  
CC rapid production of functional information from genomic sequence. The  
CC present sequence is a peptide encoded by a single exon nucleic acid  
CC probe of the invention.  
CC Note: The sequence data for this patent did not form part of the  
CC printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pcl\_sequences.

XX Sequence 68 AA;

Query Match 19.4%; Score 68; DB 22; Length 68;

Best Local Similarity 100.0%; Pred. No. 5,7e-58;  
Matches 68; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 MEEVLQKKADLLSYHPPIRPMKRITWNTWKERLVIRALENRVGISPTATDAAPGV 110  
DB 1 MEEVLQKKADLLSYHPPIRPMKRITWNTWKERLVIRALENRVGISPTATDAAPGV 60  
QY 111 NNMLAKGL 118  
DB 61 NNMLAKGL 68

## RESULT 10

ABB37667  
ID ABB37667 standard; Peptide; 68 AA.

AC ABB37667;

DT 04-FEB-2002 (first entry)

DE Peptide #5173 encoded by human foetal liver single exon probe.

XX Human; foetal liver; gene expression; single exon nucleic acid probe.

XX Homo sapiens.

PN W0200157277-A2.

PD 09-AUG-2001.

PF 30-JAN-2001; 2001MO-US00669.

PR 04-FEB-2000; 2000US-0180312.

PR 26-MAY-2000; 2000US-0207456.

PR 30-JUN-2000; 2000US-0608408.

PR 03-AUG-2000; 2000US-0632366.

PR 21-SEP-2000; 2000US-0234687.

PR 27-SEP-2000; 2000US-0236359.

PR 04-OCT-2000; 2000GB-0024263.

PA (MOLE-) MOLECULAR DYNAMICS INC.

PI Penn SG, Hanzel DK, Chen W, Rank DR;

DR WPI; 2001-483447/52.

XX Human genome-derived single exon nucleic acid probes useful for  
PT analyzing gene expression in human foetal liver -

PS Claim 27; SEQ ID NO 30302; 639pp + sequence listing; English.

XX The invention relates to a single exon nucleic acid probe for  
CC measuring human gene expression in a sample derived from human foetal  
CC liver. The single exon nucleic acid probes may be used for predicting,  
CC measuring and displaying gene expression in samples derived from human  
CC foetal liver. The present sequence is a peptide encoded by a single exon  
CC nucleic acid probe of the invention.  
CC Note: The sequence data for this patent did not form part of the  
CC printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pcl\_sequences.

XX Sequence 68 AA;

Query Match 19.4%; Score 68; DB 22; Length 68;  
Best Local Similarity 100.0%; Pred. No. 5,7e-58;  
Matches 68; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 MEEVLQKKADLLSYHPPIRPMKRITWNTWKERLVIRALENRVGISPTATDAAPGV 110  
DB 1 MEEVLQKKADLLSYHPPIRPMKRITWNTWKERLVIRALENRVGISPTATDAAPGV 60  
QY 111 NNMLAKGL 118  
DB 61 NNMLAKGL 118





XX OS Homo sapiens.  
XX PN W0200157270-A2.  
XX PD 09-AUG-2001.  
XX PF 29-JAN-2001; 2001MO-US00661.  
XX PR 04-FEB-2000; 2000US-0180312.  
PR 26-MAY-2000; 2000US-0207456.  
PR 30-JUN-2000; 2000US-0608408.  
PR 03-AUG-2000; 2000US-0632366.  
PR 21-SEP-2000; 2000US-0234687.  
PR 27-SEP-2000; 2000US-0236359.  
PR 04-OCT-2000; 2000GB-0024263.  
XX PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;  
XX DR WPI; 2001-476286/51.  
XX PT Novel single exon nucleic acid probe used to measuring gene expression  
XX PS in a human breast -  
XX PS Claim 27; SEQ ID NO 14918; 322pp; English.  
XX CC The present invention relates to novel single exon nucleic acid probes  
CC (see AA100010-AA110067). The present sequence is a peptide encoded by one  
CC such probe. The probes are useful for measuring human gene expression in  
CC a human breast sample, where the probe hybridises at high stringency to a  
CC nucleic acid expressed in the human breast. The probes are useful for  
CC predicting, diagnosing, grading, staging, monitoring and prognosing  
CC diseases of the human breast, particularly those diseases with polygenic  
CC aetiology. The diseases include: breast cancer, disorders of development,  
CC inflammatory diseases of the breast, fibrocystic changes, proliferative  
CC breast disease and non-carcinoma tumours.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_sequences.  
XX SQ Sequence 68 AA:  
Query Match 19.4%; Score 68; DB 22; Length 68;  
Best Local Similarity 100.0%; Pred. No. 5,7e-58;  
Matches 68; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 51 MEVYLOKKADLIISHPPIRPMKRTITWNTWKEKLVIRALENRVGIYSPTAYDADPGV 110  
DB 1 MEVYLOKKADLIISHPPIRPMKRTITWNTWKEKLVIRALENRVGIYSPTAYDADPGV 60  
QY 111 NNWIAKGL 118  
DB 61 NNWIAKGL 68  
RESULT 14  
AAU21467  
ID AAU21467 standard; Protein; 79 AA.  
AC AAU21467;  
XX 18-DEC-2001 (first entry)  
XX DE Human novel foetal antigen, SEQ ID NO 1711.  
XX KW Human; foetal tissue antigen; antiinflammatory; neuroprotective;  
KW immunomodulator; cardiovascular; cytosolic; nephrothropic;  
KW cardiovascular; autoimmune disease; rheumatoid arthritis;  
KW hyperproliferative disorder; breast neoplasm; cancer;  
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;  
KW cerebral ischaemia; angiogenesis; nervous system disorder;

KW Alzheimer's disease; infection; ocular disorder; corneal infection;  
KW wound healing; epithelial cell proliferation; food additive.  
XX OS Homo sapiens.  
XX PN W0200155312-A2.  
XX PD 02-AUG-2001.  
XX PF 17-JAN-2001; 2001MO-US01321.  
XX PR 31-JAN-2000; 2000US-0179065.  
PR 04-FEB-2000; 2000US-0180628.  
PR 24-FEB-2000; 2000US-0184664.  
PR 02-MAR-2000; 2000US-0186350.  
PR 16-MAR-2000; 2000US-0189874.  
PR 17-MAR-2000; 2000US-0190076.  
PR 18-APR-2000; 2000US-0198123.  
PR 19-MAY-2000; 2000US-0205515.  
PR 07-JUN-2000; 2000US-0209467.  
PR 28-JUN-2000; 2000US-0214886.  
PR 30-JUN-2000; 2000US-0215135.  
PR 07-JUL-2000; 2000US-0216647.  
PR 07-JUL-2000; 2000US-0216880.  
PR 11-JUL-2000; 2000US-0217487.  
PR 14-JUL-2000; 2000US-0218290.  
PR 26-JUL-2000; 2000US-0220963.  
PR 26-JUL-2000; 2000US-0220964.  
PR 14-AUG-2000; 2000US-0224519.  
PR 14-AUG-2000; 2000US-0224519.  
PR 14-AUG-2000; 2000US-0225213.  
PR 14-AUG-2000; 2000US-0225214.  
PR 14-AUG-2000; 2000US-0225256.  
PR 14-AUG-2000; 2000US-0225267.  
PR 14-AUG-2000; 2000US-0225268.  
PR 14-AUG-2000; 2000US-0225270.  
PR 14-AUG-2000; 2000US-0225447.  
PR 14-AUG-2000; 2000US-0225757.  
PR 14-AUG-2000; 2000US-0225758.  
PR 14-AUG-2000; 2000US-0225759.  
PR 18-AUG-2000; 2000US-0226279.  
PR 22-AUG-2000; 2000US-0226681.  
PR 22-AUG-2000; 2000US-0226868.  
PR 22-AUG-2000; 2000US-0227182.  
PR 23-AUG-2000; 2000US-0227189.  
PR 30-AUG-2000; 2000US-0228924.  
PR 01-SEP-2000; 2000US-0229287.  
PR 01-SEP-2000; 2000US-0229343.  
PR 01-SEP-2000; 2000US-0229344.  
PR 01-SEP-2000; 2000US-0229345.  
PR 05-SEP-2000; 2000US-0229509.  
PR 05-SEP-2000; 2000US-0229513.  
PR 06-SEP-2000; 2000US-0230437.  
PR 06-SEP-2000; 2000US-0230438.  
PR 06-SEP-2000; 2000US-0231242.  
PR 08-SEP-2000; 2000US-0231243.  
PR 08-SEP-2000; 2000US-0231244.  
PR 08-SEP-2000; 2000US-0231244.  
PR 08-SEP-2000; 2000US-0231413.  
PR 08-SEP-2000; 2000US-0231414.  
PR 08-SEP-2000; 2000US-0232080.  
PR 08-SEP-2000; 2000US-0232081.  
PR 12-SEP-2000; 2000US-0231968.  
PR 14-SEP-2000; 2000US-0232397.  
PR 14-SEP-2000; 2000US-0232397.  
PR 14-SEP-2000; 2000US-0232398.  
PR 14-SEP-2000; 2000US-0232399.  
PR 14-SEP-2000; 2000US-0232400.  
PR 14-SEP-2000; 2000US-0232401.  
PR 14-SEP-2000; 2000US-0233063.  
PR 14-SEP-2000; 2000US-0233064.  
PR 14-SEP-2000; 2000US-0233065.  
PR 21-SEP-2000; 2000US-0234223.  
PR 21-SEP-2000; 2000US-0234274.

PR	25-SEP-2000	2000US-02349957
PR	25-SEP-2000	2000US-02349984
PR	25-SEP-2000	2000US-02354854
PR	27-SEP-2000	2000US-02358934
PR	27-SEP-2000	2000US-02358936
PR	29-SEP-2000	2000US-02363637
PR	29-SEP-2000	2000US-02363657
PR	29-SEP-2000	2000US-02363658
PR	29-SEP-2000	2000US-02363659
PR	29-SEP-2000	2000US-02363700
PR	02-OCT-2000	2000US-02370337
PR	02-OCT-2000	2000US-02370338
PR	02-OCT-2000	2000US-02370339
PR	02-OCT-2000	2000US-02370400
PR	13-OCT-2000	2000US-02379935
PR	13-OCT-2000	2000US-02399357
PR	20-OCT-2000	2000US-02409650
PR	20-OCT-2000	2000US-02411221
PR	20-OCT-2000	2000US-02417855
PR	20-OCT-2000	2000US-02417856
PR	20-OCT-2000	2000US-02417871
PR	20-OCT-2000	2000US-02418008
PR	20-OCT-2000	2000US-02418095
PR	01-NOV-2000	2000US-02446117
PR	08-NOV-2000	2000US-02464474
PR	08-NOV-2000	2000US-02464475
PR	08-NOV-2000	2000US-02464476
PR	08-NOV-2000	2000US-02464477
PR	08-NOV-2000	2000US-02464478
PR	08-NOV-2000	2000US-02465523
PR	08-NOV-2000	2000US-02465524
PR	08-NOV-2000	2000US-02465525
PR	08-NOV-2000	2000US-02465526
PR	08-NOV-2000	2000US-02465527
PR	08-NOV-2000	2000US-02465528
PR	08-NOV-2000	2000US-02465532
PR	08-NOV-2000	2000US-02466609
PR	08-NOV-2000	2000US-02466610
PR	08-NOV-2000	2000US-02466611
PR	08-NOV-2000	2000US-02466613
PR	17-NOV-2000	2000US-02492207
PR	17-NOV-2000	2000US-02492208
PR	17-NOV-2000	2000US-02492209
PR	17-NOV-2000	2000US-02492210
PR	17-NOV-2000	2000US-02492211
PR	17-NOV-2000	2000US-02492212
PR	17-NOV-2000	2000US-02492213
PR	17-NOV-2000	2000US-02492244
PR	17-NOV-2000	2000US-02492264
PR	17-NOV-2000	2000US-02492265
PR	17-NOV-2000	2000US-02492266
PR	17-NOV-2000	2000US-02492297
PR	17-NOV-2000	2000US-02492299
PR	17-NOV-2000	2000US-02493210
PR	01-DEC-2000	2000US-02503160
PR	01-DEC-2000	2000US-02503161
PR	05-DEC-2000	2000US-02510300
PR	05-DEC-2000	2000US-02510308
PR	05-DEC-2000	2000US-02510319
PR	06-DEC-2000	2000US-02514879
PR	08-DEC-2000	2000US-02518658
PR	08-DEC-2000	2000US-02518659
PR	08-DEC-2000	2000US-02519889
PR	11-DEC-2000	2000US-02519900
PR	11-DEC-2000	2000US-02540957

XX	PI	Rosen CA,	Barash SC,	Ruben SM;
XX	DR	WPI; 2001-488782/53.		
XX	DR	N-PSDB; AAS34287.		
PT	XX	New polynucleotides and polypeptides for diagnosing, treating, PT preventing or prognosing e.g. diseases or disorders of the nervous, PT musculoskeletal, excretory, gastrointestinal, reproductive, and PT respiratory systems -		
XX	PS	Claim 11; SEQ ID NO 1711; 642bp; English.		
XX	CC	The invention relates to novel nucleic acids encoding novel human foetal CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g. CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice, CC rabbits, goats, horses, cats, dogs, chickens or sheep. They CC are also used in diagnosing a pathological condition or susceptibility CC to a pathological condition. The antibodies to the antigens can also CC be used in alleviating symptoms associated with the disorders and in CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked CC immunosorbent assays (ELISA). Disorders which are diagnosed or treated CC include autoimmune diseases e.g. rheumatoid arthritis, CC hyperproliferative disorders e.g. neoplasms of the breast or liver. CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders CC e.g. cerebral ischaemia, angiodenesis, nervous system disorders e.g. CC Alzheimer's disease, infections caused by bacteria, viruses and fungi CC and ocular disorders e.g. corneal infection. The polypeptides can also CC be used to aid wound healing and epithelial cell proliferation, to CC prevent skin aging due to sunburn, to maintain organs before CC transplantation, for supporting cell culture of primary tissues, to CC regenerate tissues and in chemotaxis. The polypeptides can also be used CC as a food additive or preservative to increase or decrease storage CC capabilities, fat content, lipid, protein, carbohydrate, vitamins, CC minerals, cofactors and other nutritional components. Numerous CC examples of diseases and disorders treated by the nucleic acids and CC proteins are given in the specification. The present sequence		
OS	Query Match	14.0%; Score 49; DB 22; Length 79; Best Local Similarity 100.0%; Pred. No. 1.9e-39; Matches 49; Conservative 0; Mismatches 39; Indels 0; Gaps 0		
OY	118 IGACTSPRIHPSKAPNYPEEGNHRYEFNVNTODLDKYSANVKIGDVS 166       15 LGACTSRPIHPSKAPNYPEEGNHRYEFNVNTODLDKYSANVKIGDVS 63			
Db	RESULT 15 ID AAU27916 AAU27916 standard; Protein; 146 AA.			
AC	AAU27916;			
XX	18-DEC-2001 (first entry)			
XX	Human contig polypeptide sequence #69.			
DE	Mammal, human; rhesus monkey; baker's yeast; fission yeast; Norway rat; KM mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia; KM lymphoma; neuroblastoma; autoimmune disorder; cell proliferation; KM nervous system disorder; inflammatory disorder; cell differentiation; KM angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn; KM genetic disorder; bone regeneration; tendon; ligament; tissue repair; KM cytoskeletal; antihumetic; antiarthritic; vulnary; antiinflammatory; KM antibacterial; immunosuppressive; vasotropic; antiparkinsonian; KM neuroprotective; osteoporotic; antidiabetic; antiaesthetic; antiallergic; KM immunostimulant; analgesic; gene therapy.			
XX	Homo sapiens.			
OS	Synthetic.			

```

XX      WO200164834-A2.
PN
XX
XX      07-SEP-2001.
PD
XX
XX      26-FEB-2001; 2001WO-US04926.
PF
XX
XX      28-FEB-2000; 2000US-0515126.
PR      18-MAY-2000; 2000US-0577409.
PR      17-JUN-2000; 2000US-0597707.
PR      14-JUL-2000; 2000US-0616807.
PR      19-SEP-2000; 2000US-0664641.
XX
XX      (HYSE-) HYSEQ INC.
PA
XX
PI      Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI      Xue AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;
PI      Drmanac R;
XX
XX      WPI; 2001-589862/66.
DR      N-PSDB; AAS44816.
DR
XX
XX      Novel polypeptides and nucleic acids obtained from cDNA libraries
PT      prepared from various human tissues, for diagnosis, treatment of
PT      cancer, neurological, inflammatory disorders and for use in arrays for
PT      detection
XX
XX      Claim 10; Page 132; 153pp; English.
PS
XX
XX      Sequences AAU27676-AAU28019 represent full-length polypeptides and
CC      contig polypeptides of the invention. The proteins and their associated
CC      DNA sequences are useful for the treatment, diagnosis and prevention of
CC      various types of disorder in a mammalian subject such as a human, dog,
CC      monkey, mouse, hamster or rat. The disorders include cancers such as
CC      leukaemia, lymphoma and neuroblastoma, autoimmune disorders such as
CC      multiple sclerosis, connective tissue disease, rheumatoid arthritis,
CC      diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
CC      disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
CC      chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
CC      Menckle disease, inflammatory disorders such as nephritis, Crohn's
CC      disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
CC      bowel disease. The sequences exhibit activity relating to angiogenesis,
CC      cell proliferation, cell differentiation, stem cell growth factor,
CC      activin or inhibin. Therefore, they can be used to manipulate stem cells
CC      in culture to give rise to neuroepithelial cells that can be used to
CC      augment or replace cells damaged by illness, accidental damage or genetic
CC      disorders. The sequences may also be used for regeneration of bone,
CC      cartilage, tendons and ligaments and in tissue repair and burn healing.
CC      Note: Some sequences for this patent did not form part of the printed
CC      specification, but were obtained in electronic format directly from WIPO
CC      at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ      Sequence      146 AA:

```

## Query Match

12.3%; Score 43; DB 22; Length 146;

Best Local Similarity 100.0%; Pred. No. 2.2e-33;

Matches 43; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      5 AIISSINDFASLSFAESMDNVGLVEPSPPHVTNTLFTINDLT 47
      |||
DB      36 AIISSINDFASLSFAESMDNVGLVEPSPPHVTNTLFTINDLT 78

```

Search completed: August 22, 2003, 15:17:00  
 Job time : 87 secs

**THIS PAGE BLANK (USPTO)**